Coronary Physiology-Guided Revascularization in Chronic and Acute Coronary Syndromes: Medical Therapy, Placebo Procedures and Culprit-Only PCI as Distinct Comparators
Journal of Clinical Medicine · 2026-11-12 · 15 (22) · 8856
DOI: 10.3390/jcm15228856 ↗Abstract
Coronary physiological assessment refines lesion selection, but the randomized evidence addressing its clinical value differs according to the treatment comparison. This narrative review examines three distinct questions: (1) percutaneous coronary intervention (PCI) plus medical therapy versus medical therapy alone in selected chronic coronary settings; (2) PCI versus a placebo procedure for symptomatic stable angina; and (3) physiology-guided complete versus culprit-lesion-only PCI in acute coronary syndromes (ACS) with multivessel disease, with medical therapy provided in both arms. We reviewed pivotal randomized studies and follow-up publications through 31 October 2026 and considered contemporary trials comparing different physiological guidance methods separately. In chronic coronary settings, FAME 2 demonstrated a reduction in urgent revascularization, ORBITA-2 established a placebo-controlled angina benefit after withdrawal of background antianginal drugs, and NOTION-3 showed fewer myocardial infarctions and urgent revascularizations in patients undergoing transcatheter aortic-valve implantation, but included lesions eligible by either fractional flow reserve (FFR) or angiographic severity. In ACS, the results of trials comparing complete with culprit-only PCI vary; several composite benefits are driven by repeat revascularization, whereas FIRE also showed a reduction in cardiovascular death or myocardial infarction. These designs cannot isolate the benefit attributable to physiological selection from the benefit of treating additional lesions. Recent trials directly comparing angiography-derived physiology with alternative guidance strategies address a different question. FFR, non-hyperemic pressure indices, and angiography-derived measurements have distinct methodological and timing considerations, particularly after infarction. Overall, symptom relief, unplanned revascularization, and death or myocardial infarction should be interpreted separately; choice of revascularization strategy should integrate clinical presentation, anatomy, physiology, patient preferences, and optimized medical therapy.
EUVIMED